IBOV 177,866 ▲ 2.97% IPSA 11,057 ▲ 0.28% IPC MEX 66,496 ▲ 0.59% MERVAL 3,280,224 ▲ 2.43% COLCAP 2,307.67 ▲ 0.65% BVL PERÚ 56,194.27 ▲ 1.29% USD/BRL5.11▼ 0.17% USD/MXN17.46▼ 0.49% USD/CLP923.90▼ 0.41% USD/COP3,240▼ 3.09% USD/PEN3.39▼ 0.31% USD/ARS1,487▼ 0.03% USD/UYU40.22▲ 1.20% USD/PYG6,055▲ 1.53% USD/BOB10.14▲ 4.01% USD/DOP58.48▼ 0.12% USD/CRC448.82▲ 1.40% USD/GTQ7.63▲ 2.28% USD/HNL26.72▲ 1.50% USD/NIO36.62▲ 0.23% USD/VES707.92▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD158.07▲ 0.80% USD/TTD6.75▲ 1.32% EUR/BRL5.83▼ 1.07% BRENT 76.01 ▼ 0.38% WTI 71.41 ▼ 0.93% IRON ORE 161.91 — — COPPER 6.28 ▲ 1.08% GOLD 4,114 ▼ 0.41% SILVER 60.17 ▼ 0.35% SOY 1,191 ▲ 0.93% CORN 461.00 ▲ 7.77% WHEAT 640.25 ▲ 4.74% COFFEE 318.60 ▼ 10.74% SUGAR 14.86 ▼ 1.72% ORANGE JUICE 143.25 ▼ 4.44% COTTON 80.87 ▲ 6.18% COCOA 6,100 ▼ 3.31% BEEF 235.20 ▼ 0.02% CATTLE 354.60 ▼ 0.44% LITHIUM 72.32 ▼ 0.69% PETR4 39.65 ▲ 1.12% VALE3 74.18 ▲ 1.41% ITUB4 44.30 ▲ 4.02% BBDC4 18.86 ▲ 4.78% ABEV3 15.82 ▲ 0.64% BBAS3 20.58 ▲ 2.90% B3SA3 15.42 ▲ 4.26% WEGE3 46.51 ▲ 1.68% PRIO3 55.45 ▼ 0.29% SUZB3 41.55 ▲ 1.27% AZZA3 19.10 ▲ 3.47% CSAN3 4.07 ▲ 5.44% RAIZ4 0.35 ▼ 5.41% PCAR3 2.73 ▼ 1.09% GMAT3 3.97 ▲ 1.02% PSSA3 54.97 ▲ 3.04% CVCB3 1.25 — 0.00% POSI3 3.97 ▲ 3.12% SLCE3 14.02 ▲ 1.67% NATU3 8.68 ▲ 2.60% BRKM5 6.63 ▲ 4.25% RANI3 8.01 ▲ 1.91% CSNA3 5.18 ▲ 7.92% CMIN3 5.23 ▲ 8.28% USIM5 8.45 ▲ 1.20% GGBR4 23.01 ▲ 2.36% ENEV3 27.55 ▲ 5.15% CPFE3 47.87 ▲ 3.41% CMIG4 11.38 ▲ 2.71% EQTL3 40.91 ▲ 3.54% LREN3 14.62 ▲ 3.32% VIVT3 35.75 ▲ 3.62% RAIL3 14.36 ▲ 4.44% KLABIN 17.54 ▲ 0.80% RAIA DROGASIL 18.77 ▲ 3.53% RDOR3 36.02 ▲ 2.48% HAPV3 10.60 ▲ 5.26% FLRY3 16.42 ▲ 4.25% SMTO3 16.37 ▲ 1.99% UGPA3 30.71 ▲ 2.03% VBBR3 33.00 ▲ 2.80% BBSE3 40.35 ▲ 2.72% BPAC11 58.73 ▲ 5.48% CURY3 34.21 ▲ 4.62% AERI3 2.09 ▲ 1.46% VIVARA 23.53 ▲ 4.21% COMPASS 25.50 ▲ 3.32% VAMOS 3.06 ▲ 3.38% SANB11 27.62 ▲ 5.22% ASAI3 8.87 ▲ 4.85% SBSP3 31.11 ▲ 3.70% WALMEX 49.31 ▲ 0.59% GMEXICO 198.62 ▲ 1.68% FEMSA 223.20 ▲ 0.37% CEMEX 21.82 ▲ 0.51% GFNORTE 186.51 ▲ 0.63% BIMBO 56.06 ▲ 0.23% TELEVISA 9.74 ▲ 2.63% AMX 22.70 ▲ 0.27% GAP 412.01 ▼ 0.41% ASUR 285.12 ▲ 0.53% OMA 235.73 ▼ 0.95% KOF 182.08 ▲ 0.65% GRUMA 282.99 ▲ 0.14% KIMBER 38.13 ▼ 0.81% SQM-B 67,750 ▼ 1.95% COPEC 6,139 ▲ 1.98% BSANTANDER 79.00 ▲ 1.94% FALABELLA 5,905 ▲ 0.92% ENELAM 85.40 ▲ 1.47% CENCOSUD 2,045 ▼ 0.55% CMPC 1,109 ▲ 1.32% BANCO CHILE 188.88 ▲ 1.01% LATAM AIR 26.26 ▼ 0.53% YPF 74,450 ▼ 1.75% GGAL 8,350 ▲ 5.96% PAMPA 5,185 ▼ 0.38% TXAR 671.00 ▲ 0.98% ALUAR 978.00 ▲ 0.98% TGS 9,610 ▲ 3.22% CEPU 2,405 ▲ 3.89% MIRGOR 17,375 ▲ 1.02% COME 45.90 ▲ 1.06% LOMA NEGRA 3,583 ▲ 2.43% BYMA 314.00 ▲ 1.37% TELECOM ARG 4,248 ▲ 3.09% ECOPETROL 15.59 ▲ 1.27% BANCOLOMBIA 82.95 ▲ 2.50% GRUPO AVAL 5.08 ▲ 1.20% CREDICORP 400.81 ▲ 2.27% SOUTHERN COPPER 175.83 ▲ 0.80% BUENAVENTURA 30.00 ▲ 1.52% MERCADOLIBRE 1,852 ▲ 2.46% NUBANK 13.76 ▲ 0.66% XP 16.92 ▲ 3.11% PAGSEGURO 9.25 ▲ 2.78% STONE 11.21 ▲ 2.28% GLOBANT 29.96 ▼ 4.25% TECNOGLASS 43.90 ▲ 1.76% GAP AIRPORT 235.64 ▲ 0.50% ASUR 285.12 ▲ 0.53% OMA AIRPORT 108.09 ▼ 0.22% AMX ADR 26.04 ▲ 0.77% FEMSA ADR 127.70 ▲ 0.55% CEMEX ADR 12.48 ▲ 0.89% PETROBRAS ADR 17.32 ▲ 1.70% VALE ADR 14.46 ▲ 1.69% ITAU ADR 8.62 ▲ 4.11% SANTANDER BR 5.39 ▲ 4.86% AMBEV ADR 3.07 ▲ 0.99% CSN 1.01 ▲ 5.79% GERDAU 4.50 ▲ 2.04% LATAM ADR 56.45 ▼ 1.03% BTC 64,342 ▲ 0.34% ETH 1,822 ▲ 1.45% SOL 78.13 ▲ 0.08% XRP 1.11 ▲ 0.84% BNB 580.72 ▲ 0.99% ADA 0.17 ▲ 2.15% DOGE 0.08 ▲ 1.38% AVAX 6.73 ▼ 0.11% LINK 8.04 ▲ 0.97% DOT 0.88 ▼ 0.16% LTC 45.37 ▲ 1.38% BCH 247.35 ▲ 0.85% TRX 0.33 ▲ 0.14% XLM 0.19 ▲ 0.76% HBAR 0.07 ▼ 1.09% NEAR 1.91 ▲ 0.86% ATOM 1.60 ▲ 0.86% AAVE 100.91 ▲ 5.40% SELIC 14.25% RENT3 41.10 ▲ 4.31% EMBRAER 84.60 ▲ 0.88% EMBRAER ADR 66.01 ▲ 0.72% JBS 11.91 ▲ 1.53% JBS BDR 60.78 ▲ 1.22% MBRF3 15.55 ▲ 0.91% MBRFY 2.97 ▼ 1.00% INTER 5.82 ▲ 1.93% EGX 52,312 ▲ 0.54% USD/ZAR16.35— 0.00% USD/NGN1,376▼ 0.12% NIKKEI 68,558 ▲ 1.20% CSI300 4,781 ▼ 1.96% HSI 24,175 ▲ 0.60% NIFTY 24,207 ▲ 1.02% KOSPI 7,476 ▲ 2.52% JCI 5,924 ▲ 0.20% USD/JPY161.67▼ 0.44% USD/CNY6.77▼ 0.15% DAX 25,067 ▼ 0.20% CAC 8,339 ▲ 0.15% FTSE 10,497 ▲ 0.24% MIB 52,614 ▲ 0.44% IBEX 19,385 ▲ 0.32% STOXX 641.10 ▲ 0.04% EUR/USD1.14▼ 0.10% GBP/USD1.34▲ 0.01% SPX 7,575 ▲ 0.42% DJI 52,637 ▲ 0.29% NDX 29,825 ▲ 0.33% RUT 2,978 ▼ 0.49% TSX 35,305 ▲ 0.30% VIX 15.03 ▼ 5.11% USD/CAD1.42— 0.00% US10Y 4.5690 ▲ 0.66% IBOV 177,866 ▲ 2.97% IPSA 11,057 ▲ 0.28% IPC MEX 66,496 ▲ 0.59% MERVAL 3,280,224 ▲ 2.43% COLCAP 2,307.67 ▲ 0.65% BVL PERÚ 56,194.27 ▲ 1.29% USD/BRL 5.11 ▼ 0.17% USD/MXN 17.46 ▼ 0.49% USD/CLP 923.90 ▼ 0.41% USD/COP 3,240 ▼ 3.09% USD/PEN 3.39 ▼ 0.31% USD/ARS 1,487 ▼ 0.03% USD/UYU 40.22 ▲ 1.20% USD/PYG 6,055 ▲ 1.53% USD/BOB 10.14 ▲ 4.01% USD/DOP 58.48 ▼ 0.12% USD/CRC 448.82 ▲ 1.40% USD/GTQ 7.63 ▲ 2.28% USD/HNL 26.72 ▲ 1.50% USD/NIO 36.62 ▲ 0.23% USD/VES 707.92 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 158.07 ▲ 0.39% USD/TTD 6.75 ▲ 1.44% EUR/BRL 5.83 ▼ 1.07% BRENT 76.01 ▼ 0.38% WTI 71.41 ▼ 0.93% IRON ORE 161.91 — — COPPER 6.28 ▲ 1.08% GOLD 4,114 ▼ 0.41% SILVER 60.17 ▼ 0.35% SOY 1,191 ▲ 0.93% CORN 461.00 ▲ 7.77% WHEAT 640.25 ▲ 4.74% COFFEE 318.60 ▼ 10.74% SUGAR 14.86 ▼ 1.72% ORANGE JUICE 143.25 ▼ 4.44% COTTON 80.87 ▲ 6.18% COCOA 6,100 ▼ 3.31% BEEF 235.20 ▼ 0.02% CATTLE 354.60 ▼ 0.44% LITHIUM 72.32 ▼ 0.69% PETR4 39.65 ▲ 1.12% VALE3 74.18 ▲ 1.41% ITUB4 44.30 ▲ 4.02% BBDC4 18.86 ▲ 4.78% ABEV3 15.82 ▲ 0.64% BBAS3 20.58 ▲ 2.90% B3SA3 15.42 ▲ 4.26% WEGE3 46.51 ▲ 1.68% PRIO3 55.45 ▼ 0.29% SUZB3 41.55 ▲ 1.27% AZZA3 19.10 ▲ 3.47% CSAN3 4.07 ▲ 5.44% RAIZ4 0.35 ▼ 5.41% PCAR3 2.73 ▼ 1.09% GMAT3 3.97 ▲ 1.02% PSSA3 54.97 ▲ 3.04% CVCB3 1.25 — 0.00% POSI3 3.97 ▲ 3.12% SLCE3 14.02 ▲ 1.67% NATU3 8.68 ▲ 2.60% BRKM5 6.63 ▲ 4.25% RANI3 8.01 ▲ 1.91% CSNA3 5.18 ▲ 7.92% CMIN3 5.23 ▲ 8.28% USIM5 8.45 ▲ 1.20% GGBR4 23.01 ▲ 2.36% ENEV3 27.55 ▲ 5.15% CPFE3 47.87 ▲ 3.41% CMIG4 11.38 ▲ 2.71% EQTL3 40.91 ▲ 3.54% LREN3 14.62 ▲ 3.32% VIVT3 35.75 ▲ 3.62% RAIL3 14.36 ▲ 4.44% KLABIN 17.54 ▲ 0.80% RAIA DROGASIL 18.77 ▲ 3.53% RDOR3 36.02 ▲ 2.48% HAPV3 10.60 ▲ 5.26% FLRY3 16.42 ▲ 4.25% SMTO3 16.37 ▲ 1.99% UGPA3 30.71 ▲ 2.03% VBBR3 33.00 ▲ 2.80% BBSE3 40.35 ▲ 2.72% BPAC11 58.73 ▲ 5.48% CURY3 34.21 ▲ 4.62% AERI3 2.09 ▲ 1.46% VIVARA 23.53 ▲ 4.21% COMPASS 25.50 ▲ 3.32% VAMOS 3.06 ▲ 3.38% SANB11 27.62 ▲ 5.22% ASAI3 8.87 ▲ 4.85% SBSP3 31.11 ▲ 3.70% WALMEX 49.31 ▲ 0.59% GMEXICO 198.62 ▲ 1.68% FEMSA 223.20 ▲ 0.37% CEMEX 21.82 ▲ 0.51% GFNORTE 186.51 ▲ 0.63% BIMBO 56.06 ▲ 0.23% TELEVISA 9.74 ▲ 2.63% AMX 22.70 ▲ 0.27% GAP 412.01 ▼ 0.41% ASUR 285.12 ▲ 0.53% OMA 235.73 ▼ 0.95% KOF 182.08 ▲ 0.65% GRUMA 282.99 ▲ 0.14% KIMBER 38.13 ▼ 0.81% SQM-B 67,750 ▼ 1.95% COPEC 6,139 ▲ 1.98% BSANTANDER 79.00 ▲ 1.94% FALABELLA 5,905 ▲ 0.92% ENELAM 85.40 ▲ 1.47% CENCOSUD 2,045 ▼ 0.55% CMPC 1,109 ▲ 1.32% BANCO CHILE 188.88 ▲ 1.01% LATAM AIR 26.26 ▼ 0.53% YPF 74,450 ▼ 1.75% GGAL 8,350 ▲ 5.96% PAMPA 5,185 ▼ 0.38% TXAR 671.00 ▲ 0.98% ALUAR 978.00 ▲ 0.98% TGS 9,610 ▲ 3.22% CEPU 2,405 ▲ 3.89% MIRGOR 17,375 ▲ 1.02% COME 45.90 ▲ 1.06% LOMA NEGRA 3,583 ▲ 2.43% BYMA 314.00 ▲ 1.37% TELECOM ARG 4,248 ▲ 3.09% ECOPETROL 15.59 ▲ 1.27% BANCOLOMBIA 82.95 ▲ 2.50% GRUPO AVAL 5.08 ▲ 1.20% CREDICORP 400.81 ▲ 2.27% SOUTHERN COPPER 175.83 ▲ 0.80% BUENAVENTURA 30.00 ▲ 1.52% MERCADOLIBRE 1,852 ▲ 2.46% NUBANK 13.76 ▲ 0.66% XP 16.92 ▲ 3.11% PAGSEGURO 9.25 ▲ 2.78% STONE 11.21 ▲ 2.28% GLOBANT 29.96 ▼ 4.25% TECNOGLASS 43.90 ▲ 1.76% GAP AIRPORT 235.64 ▲ 0.50% ASUR 285.12 ▲ 0.53% OMA AIRPORT 108.09 ▼ 0.22% AMX ADR 26.04 ▲ 0.77% FEMSA ADR 127.70 ▲ 0.55% CEMEX ADR 12.48 ▲ 0.89% PETROBRAS ADR 17.32 ▲ 1.70% VALE ADR 14.46 ▲ 1.69% ITAU ADR 8.62 ▲ 4.11% SANTANDER BR 5.39 ▲ 4.86% AMBEV ADR 3.07 ▲ 0.99% CSN 1.01 ▲ 5.79% GERDAU 4.50 ▲ 2.04% LATAM ADR 56.45 ▼ 1.03% BTC 64,342 ▲ 0.34% ETH 1,822 ▲ 1.45% SOL 78.13 ▲ 0.08% XRP 1.11 ▲ 0.84% BNB 580.72 ▲ 0.99% ADA 0.17 ▲ 2.15% DOGE 0.08 ▲ 1.38% AVAX 6.73 ▼ 0.11% LINK 8.04 ▲ 0.97% DOT 0.88 ▼ 0.16% LTC 45.37 ▲ 1.38% BCH 247.35 ▲ 0.85% TRX 0.33 ▲ 0.14% XLM 0.19 ▲ 0.76% HBAR 0.07 ▼ 1.09% NEAR 1.91 ▲ 0.86% ATOM 1.60 ▲ 0.86% AAVE 100.91 ▲ 5.40% SELIC 14.25% RENT3 41.10 ▲ 4.31% EMBRAER 84.60 ▲ 0.88% EMBRAER ADR 66.01 ▲ 0.72% JBS 11.91 ▲ 1.53% JBS BDR 60.78 ▲ 1.22% MBRF3 15.55 ▲ 0.91% MBRFY 2.97 ▼ 1.00% INTER 5.82 ▲ 1.93% EGX 52,312 ▲ 0.54% USD/ZAR 16.35 ▲ 0.24% USD/NGN 1,376 ▲ 0.08% NIKKEI 68,558 ▲ 1.20% CSI300 4,781 ▼ 1.96% HSI 24,175 ▲ 0.60% NIFTY 24,207 ▲ 1.02% KOSPI 7,476 ▲ 2.52% JCI 5,924 ▲ 0.20% USD/JPY 161.67 ▼ 0.42% USD/CNY 6.7667 ▼ 0.37% DAX 25,067 ▼ 0.20% CAC 8,339 ▲ 0.15% FTSE 10,497 ▲ 0.24% MIB 52,614 ▲ 0.44% IBEX 19,385 ▲ 0.32% STOXX 641.10 ▲ 0.04% EUR/USD 1.1419 ▼ 0.13% GBP/USD 1.3398 ▼ 0.04% SPX 7,575 ▲ 0.42% DJI 52,637 ▲ 0.29% NDX 29,825 ▲ 0.33% RUT 2,978 ▼ 0.49% TSX 35,305 ▲ 0.30% VIX 15.03 ▼ 5.11% USD/CAD 1.4153 ▼ 0.09% US10Y 4.5690 ▲ 0.66%
since 2009
Saturday, July 11, 2026

Covid-19: Why all the fuss about Ivermectin, that became in many countries a ‘dirty word’?

By · September 20, 2021 · 5 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – First hydroxychloroquine, and now ivermectin; it is one of the most warned about drugs, criticized by the medical establishment and regulatory authorities in many countries. However, both drugs have long existed as FDA-approved prescription medications for several diseases. But now, people are being told that they are deadly and very dangerous.

Ivermectin was approved by the FDA in 1998 under the brand name Stromectol, produced by the pharmaceutical giant Merck, and approved for various parasitic infections, principally in large animals. The product label described it as having a “unique mode of action,” which “leads to an increase in cell membrane permeability to chloride ions.”

One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →

Read also: Check out our coverage on Dissenter’s Voice

This suggests that ivermectin acts as an ionophore, making cell membranes permeable to ions entering the cell for therapeutic effect. Safety data for these vaccines are relatively limited, but the WHO has identified two serious adverse events that could be linked to Sinopharm’s.

Why all the fuss about ivermectin, that became in many countries a 'dirty word'
Why all the fuss about ivermectin that became in many countries a ‘dirty word’. (Photo internet reproduction)
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Ivermectin is one of several ionophores, others include hydroxychloroquine, quercetin, and resveratrol, the latter two available over-the-counter. These ionophores open a cellular door, allowing zinc to enter the cell, where it then interferes with viral replication, providing potential therapeutic benefit in viral and other infections.

This scientific article reviews and references other studies are demonstrating the antibacterial, antiviral and anticancer properties of ivermectin. This explains the interest in this drug as having potential use in the treatment of Covid-19.

DOES IVERMECTIN WORK AGAINST COVID?

This article is not trying to answer this question but instead looking for readily available information because this drug has been the focus of much media attention recently.

What is newsworthy about ivermectin? A simple Google search of most drugs describes the uses and side effects of the searched medication. However, a similar search for ivermectin provides headlines for why it should not be taken for Covid-19 and how dangerous it is.

The Guardian describes ivermectin as a horse drug and reminds readers, considering taking medicine, and echoing a post by the FDA, “You’re not a horse. You’re not a cow,” saying it is a drug intended for farm animals. The FDA echoed that sentiment in a recent tweet.

https://twitter.com/us_fda/status/1429050070243192839

The FDA says ivermectin “can be dangerous and even lethal,” but they approved it in 1998 and did not remove it from the market despite being “dangerous and lethal.” Any drug can be “dangerous and lethal” if misused. People have even overdosed on water.

Indeed, ivermectin is also used in animals, as are many drugs approved for human use. This list of veterinary drugs with many familiar names of antibiotics, antihypertensive, and anesthetics commonly used by humans.

Since these drugs are used in farm animals, should humans stop taking them? That seems like a pretty unscientific argument against ivermectin, especially coming from the FDA. And health professionals do not recommend or prescribe animal versions of ivermectin, as there is an FDA-approved human formulation.

Does ivermectin work against Covid? That is the more important question worthy of investigation, rather than reminding people that they are not cows.

A study published several months ago in the American Journal of Therapeutics concluded:

-Meta-analyses based on 18 randomized controlled treatment trials of ivermectin against COVID-19 have found large and statistically significant reductions in mortality, time to clinical recovery, and viral clearance. In addition, results from numerous controlled prophylaxis trials report a significant reduction of the risks of contracting Covid-19 with regular use of ivermectin. Finally, the multiple examples of ivermectin distribution campaigns leading to a rapid decrease in population-wide morbidity and mortality indicate that an effective oral agent has been identified in all phases of Covid-19-. (American Journal of Therapeutics)

For now, these 18 studies have not been retracted, unlike previous studies critical of hydroxychloroquine that were ignominiously retracted by prestigious medical journals such as The Lancet and New England Journal of Medicine. [Dr. Stella Immanuel sues CNN after hydroxychloroquine was vindicated against COVID-19].

However, the medical establishment refuses even to consider the possibility of any benefit from ivermectin, punishing doctors who want to try it on their patients. 18 studies found benefit. Are they all wrong?

Highly unvaccinated Indian state Uttar Pradesh, with 210 million inhabitants, roughly the same population as the whole of Brazil, had a surge in Covid cases earlier this year that ended abruptly after widespread use of ivermectin, despite objections and criticism from WHO. In another state, however, Tamil Nadu, that did not use ivermectin, cases tripled instead of declining dramatically as in the rest of the country. This is why Indian lawyers took legal action against WHO chief scientist for suppressing data on ivermectin to treat Covid.

This is anecdotal and could have other explanations, but the discovery of penicillin was also anecdotal and observational. Good science should investigate rather than ignore such observations.

The Tokyo Medical Association recently approved the use of ivermectin as a treatment for Covid-19. The US CDC, at about the same time, warned against it. However, the Japanese association only can make suggestions but cannot enact government policies.

There was a legal backlash when an Ohio judge ordered a hospital to treat a Covid patient with ivermectin. After a month intubated, this patient is likely to be Covid-free, and ivermectin will now have no benefit, which could allow the medical establishment to say, “I told you so,” which would not help.

At this point, active Covid infection is not the issue; instead, it is weaning and recovery of long-term life support. Early studies of hydroxychloroquine had the same flaw, treating patients too late in the disease to provide or demonstrate benefit.

These drugs have been proposed for early outpatient treatment, not when patients are critically ill and close to death. Seeking treatment benefits in the wrong patient population will produce the expected negative results.

Despite high vaccination levels in countries such as the US, UK, and Israel, we see an increase in cases and hospitalizations among the vaccinated.

Medical treatment involves balancing risks and benefits. When FDA-approved drugs are used in appropriate doses for appropriate patients, prescribed by competent physicians, the risks tend to be low and any benefits should be celebrated.

In contrast, the medical establishment, the media, and regulatory authorities are taking the opposite approach.

Why is this now controversial?

Join us on Telegram: t.me/theriotimes

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.